ER7 Fundamental Analysis - ERAMET

Fundamental Rating

ER7 gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 36 industry peers in the Metals & Mining industry. ER7 may be in some trouble as it scores bad on both profitability and health. ER7 does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ER7 has reported negative net income.

In the past year ER7 has reported a negative cash flow from operations.

Of the past 5 years ER7 4 years were profitable.

Of the past 5 years ER7 4 years had a positive operating cash flow.

1.2 Ratios

ER7's Return On Assets of -1.58% is on the low side compared to the rest of the industry. ER7 is outperformed by 66.67% of its industry peers.

With a Return On Equity value of -9.29%, ER7 is not doing good in the industry: 75.00% of the companies in the same industry are doing better.

ER7's Return On Invested Capital of 0.80% is on the low side compared to the rest of the industry. ER7 is outperformed by 72.22% of its industry peers.

ER7 had an Average Return On Invested Capital over the past 3 years of 7.29%. This is in line with the industry average of 7.87%.

The last Return On Invested Capital (0.80%) for ER7 is well below the 3 year average (7.29%), which needs to be investigated, but indicates that ER7 had better years and this may not be a problem.

		Industry Rank	Sector Rank
ROA	-1.58%
ROE	-9.29%
ROIC	0.8%

ROA(3y)4.1%

ROA(5y)1.33%

ROE(3y)16.44%

ROE(5y)-1.91%

ROIC(3y)7.29%

ROIC(5y)7.73%

1.3 Margins

ER7's Profit Margin has declined in the last couple of years.

ER7 has a worse Operating Margin (1.91%) than 72.22% of its industry peers.

In the last couple of years the Operating Margin of ER7 has declined.

With an excellent Gross Margin value of 68.15%, ER7 belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.

ER7's Gross Margin has improved in the last couple of years.

		Industry Rank	Sector Rank
OM	1.91%
PM (TTM)	N/A
GM	68.15%

OM growth 3Y-46.5%

OM growth 5Y-18.83%

PM growth 3Y-61.12%

PM growth 5YN/A

GM growth 3Y-3.21%

GM growth 5Y23.96%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ER7 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.

Compared to 1 year ago, ER7 has more shares outstanding

The number of shares outstanding for ER7 has been increased compared to 5 years ago.

The debt/assets ratio for ER7 has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 1.08, we must say that ER7 is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of ER7 (1.08) is worse than 75.00% of its industry peers.

ER7 has a Debt/Equity ratio of 2.03. This is a high value indicating a heavy dependency on external financing.

With a Debt to Equity ratio value of 2.03, ER7 is not doing good in the industry: 91.67% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	2.03
Debt/FCF	N/A
Altman-Z	1.08

ROIC/WACC0.09

WACC9.24%

2.3 Liquidity

ER7 has a Current Ratio of 1.54. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.

With a Current ratio value of 1.54, ER7 is not doing good in the industry: 66.67% of the companies in the same industry are doing better.

A Quick Ratio of 1.06 indicates that ER7 should not have too much problems paying its short term obligations.

ER7's Quick ratio of 1.06 is in line compared to the rest of the industry. ER7 outperforms 41.67% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.54
Quick Ratio	1.06

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ER7 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -221.18%.

ER7 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -64.00% yearly.

The Revenue has decreased by -6.91% in the past year.

ER7 shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.39% yearly.

EPS 1Y (TTM)-221.18%

EPS 3Y-64%

EPS 5YN/A

EPS Q2Q%-268.75%

Revenue 1Y (TTM)-6.91%

Revenue growth 3Y-7.18%

Revenue growth 5Y-4.39%

Sales Q2Q%-3.31%

3.2 Future

Based on estimates for the next years, ER7 will show a very negative growth in Earnings Per Share. The EPS will decrease by -26.37% on average per year.

Based on estimates for the next years, ER7 will show a quite strong growth in Revenue. The Revenue will grow by 8.00% on average per year.

EPS Next Y-109.87%

EPS Next 2Y-56.27%

EPS Next 3Y-26.37%

EPS Next 5YN/A

Revenue Next Year3.03%

Revenue Next 2Y7.1%

Revenue Next 3Y8%

Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ER7. In the last year negative earnings were reported.

Also next year ER7 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ER7 is valued a bit more expensive than 61.11% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	14.55

4.3 Compensation for Growth

ER7's earnings are expected to decrease with -26.37% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-56.27%

EPS Next 3Y-26.37%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ER7 has a Yearly Dividend Yield of 2.67%. Purely for dividend investing, there may be better candidates out there.

Compared to an average industry Dividend Yield of 2.61, ER7 pays a bit more dividend than its industry peers.

Compared to an average S&P500 Dividend Yield of 2.31, ER7 has a dividend comparable with the average S&P500 company.

		Industry Rank	Sector Rank
Dividend Yield	2.67%

5.2 History

Dividend Growth(5Y)N/A

Div Incr Years0

Div Non Decr Years1

5.3 Sustainability

The earnings of ER7 are negative and hence is the payout ratio. ER7 will probably not be able to sustain this dividend level.

DP-44.33%

EPS Next 2Y-56.27%

EPS Next 3Y-26.37%

More info and screens

Find the best dividend stocks

Show peers with best dividend

ERAMET

FRA:ER7 (12/5/2025, 7:00:00 PM)

51.45

+1.05 (+2.08%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryMetals & Mining

Earnings (Last)10-30 2025-10-30

Earnings (Next)02-17 2026-02-17/amc

Inst Owners15.59%

Inst Owner ChangeN/A

Ins Owners0.17%

Ins Owner ChangeN/A

Market Cap1.48B

Revenue(TTM)2.88B

Net Income(TTM)-97.00M

Analysts52.73

Price Target53.14 (3.28%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	2.67%

Yearly Dividend1.51

Dividend Growth(5Y)N/A

DP-44.33%

Div Incr Years0

Div Non Decr Years1

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)1.49%

PT rev (3m)-7.36%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)95.13%

EPS NY rev (3m)94.35%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-1.78%

Revenue NY rev (3m)-3.55%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.51
P/FCF	N/A
P/OCF	N/A
P/B	1.42
P/tB	2.74
EV/EBITDA	14.55

EPS(TTM)-3.44

EYN/A

EPS(NY)-1.86

Fwd EYN/A

FCF(TTM)-25.76

FCFYN/A

OCF(TTM)-4.59

OCFYN/A

SpS100.31

BVpS36.3

TBVpS18.78

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-1.58%
ROE	-9.29%
ROCE	1.16%
ROIC	0.8%
ROICexc	0.95%
ROICexgc	1.09%
OM	1.91%
PM (TTM)	N/A
GM	68.15%
FCFM	N/A

ROA(3y)4.1%

ROA(5y)1.33%

ROE(3y)16.44%

ROE(5y)-1.91%

ROIC(3y)7.29%

ROIC(5y)7.73%

ROICexc(3y)10.98%

ROICexc(5y)11.38%

ROICexgc(3y)12.91%

ROICexgc(5y)13.43%

ROCE(3y)10.76%

ROCE(5y)11.32%

ROICexgc growth 3Y-56.22%

ROICexgc growth 5Y-25.38%

ROICexc growth 3Y-55.33%

ROICexc growth 5Y-24.94%

OM growth 3Y-46.5%

OM growth 5Y-18.83%

PM growth 3Y-61.12%

PM growth 5YN/A

GM growth 3Y-3.21%

GM growth 5Y23.96%

F-Score2

Asset Turnover0.47

Health

		Industry Rank	Sector Rank
Debt/Equity	2.03
Debt/FCF	N/A
Debt/EBITDA	10.29
Cap/Depr	403.31%
Cap/Sales	21.11%
Interest Coverage	0.34
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.54
Quick Ratio	1.06
Altman-Z	1.08

F-Score2

WACC9.24%

ROIC/WACC0.09

Cap/Depr(3y)260.42%

Cap/Depr(5y)209.27%

Cap/Sales(3y)18.57%

Cap/Sales(5y)15.29%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-221.18%

EPS 3Y-64%

EPS 5YN/A

EPS Q2Q%-268.75%

EPS Next Y-109.87%

EPS Next 2Y-56.27%

EPS Next 3Y-26.37%

EPS Next 5YN/A

Revenue 1Y (TTM)-6.91%

Revenue growth 3Y-7.18%

Revenue growth 5Y-4.39%

Sales Q2Q%-3.31%

Revenue Next Year3.03%

Revenue Next 2Y7.1%

Revenue Next 3Y8%

Revenue Next 5YN/A

EBIT growth 1Y-51.75%

EBIT growth 3Y-50.34%

EBIT growth 5Y-22.39%

EBIT Next Year-12.75%

EBIT Next 3Y24.29%

EBIT Next 5YN/A

FCF growth 1Y-850%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-121.46%

OCF growth 3YN/A

OCF growth 5YN/A

ERAMET / ER7.DE FAQ

What is the fundamental rating for ER7 stock?

ChartMill assigns a fundamental rating of 2 / 10 to ER7.DE.

What is the valuation status for ER7 stock?

ChartMill assigns a valuation rating of 0 / 10 to ERAMET (ER7.DE). This can be considered as Overvalued.

What is the profitability of ER7 stock?

ERAMET (ER7.DE) has a profitability rating of 3 / 10.

How financially healthy is ERAMET?

The financial health rating of ERAMET (ER7.DE) is 2 / 10.

Can you provide the dividend sustainability for ER7 stock?

The dividend rating of ERAMET (ER7.DE) is 2 / 10 and the dividend payout ratio is -44.33%.

ERAMET (ER7.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

5.2 History

5.3 Sustainability

More info and screens

ERAMET / ER7.DE FAQ

What is the fundamental rating for ER7 stock?

What is the valuation status for ER7 stock?

What is the profitability of ER7 stock?

How financially healthy is ERAMET?

Can you provide the dividend sustainability for ER7 stock?